↓ Skip to main content

A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case…

Overview of attention for article published in BMC Pharmacology and Toxicology, January 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#15 of 408)
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
policy
1 policy source
twitter
14 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
133 Dimensions

Readers on

mendeley
359 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study
Published in
BMC Pharmacology and Toxicology, January 2013
DOI 10.1186/2050-6511-14-1
Pubmed ID
Authors

Suzanne Dunne, Bill Shannon, Colum Dunne, Walter Cullen

Abstract

Generic medicines are those where patent protection has expired, and which may be produced by manufacturers other than the innovator company. Use of generic medicines has been increasing in recent years, primarily as a cost saving measure in healthcare provision. Generic medicines are typically 20 to 90% cheaper than originator equivalents. Our objective is to provide a high-level description of what generic medicines are and how they differ, at a regulatory and legislative level, from originator medicines. We describe the current and historical regulation of medicines in the world's two main pharmaceutical markets, in addition to the similarities, as well as the differences, between generics and their originator equivalents including the reasons for the cost differences seen between originator and generic medicines. Ireland is currently poised to introduce generic substitution and reference pricing. This article refers to this situation as an exemplar of a national system on the cusp of significant health policy change, and specifically details Ireland's history with usage of generic medicines and how the proposed changes could affect healthcare provision.

Twitter Demographics

The data shown below were collected from the profiles of 14 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 359 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Ireland 2 <1%
Colombia 1 <1%
Netherlands 1 <1%
Germany 1 <1%
Brazil 1 <1%
United Kingdom 1 <1%
Unknown 352 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 78 22%
Student > Bachelor 69 19%
Student > Ph. D. Student 31 9%
Researcher 28 8%
Student > Postgraduate 25 7%
Other 52 14%
Unknown 76 21%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 82 23%
Medicine and Dentistry 67 19%
Chemistry 26 7%
Agricultural and Biological Sciences 21 6%
Biochemistry, Genetics and Molecular Biology 15 4%
Other 58 16%
Unknown 90 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 September 2019.
All research outputs
#1,116,302
of 21,463,092 outputs
Outputs from BMC Pharmacology and Toxicology
#15
of 408 outputs
Outputs of similar age
#11,876
of 293,049 outputs
Outputs of similar age from BMC Pharmacology and Toxicology
#1
of 18 outputs
Altmetric has tracked 21,463,092 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 408 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 293,049 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.